The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

GP leaders have warned that the rollout of the weight loss drug tirzepatide (Mounjaro, Eli Lilly) will still have ...

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.

The trial enrolled 751 adults with obesity or overweight conditions and at least one weight-related medical problem ...

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

Tirzepatide has been shown in clinical trials to be more effective than diet and exercise support alone, and when compared ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

Following its endorsement of Eli Lilly’s obesity medicine tirzepatide, England’s National Institute for Health and Care ...

In the trail, 11 participants in the azelaprag group exhibited transaminase elevations without significant symptoms.

Weight loss jab tirzepatide – commonly sold under the brand name Mounjaro – is set to become available via the NHS for ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.